Patents by Inventor Suguru Takaki
Suguru Takaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240058452Abstract: A pharmaceutical composition includes a drug and a temperature-responsive ionic liquid, wherein an anion in the temperature-responsive ionic liquid includes at least one selected from the group consisting of an aromatic carboxylate ion and an aromatic sulfonate ion, and is an anion represented by formula (I) and/or formula (II): wherein, in formula (II), R1 represents a hydrogen atom or an acyl group and R2 represents an alkyl group optionally substituted with a halogen atom, a halogen atom or a sulfo group.Type: ApplicationFiled: October 8, 2020Publication date: February 22, 2024Inventors: Takahiro Motoshiromizu, Masafumi Sudo, Suguru Takaki, Mikito Hirakata, Yuri Kajiwara
-
Patent number: 11185509Abstract: A solid preparation includes a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, which is stable to light even without light shielding coating. The solid preparation includes an active ingredient composed of a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, and one or more stabilizing agents selected from the group consisting of n-propyl gallate, sodium hydrogensulfite, dibutylhydroxytoluene, butylhydroxyanisole, tocopherol and D-isoascorbic acid, wherein the amount of the above active ingredient is 0.00001 to 0.01% by weight of the solid preparation, and the amount of the above stabilizing agent is 0.005 to 5% by weight of the solid preparation.Type: GrantFiled: July 28, 2017Date of Patent: November 30, 2021Assignee: Toray Industries, Inc.Inventors: Suguru Takaki, Satoshi Minakami, Kotoe Ohta
-
Patent number: 11071734Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.Type: GrantFiled: March 30, 2018Date of Patent: July 27, 2021Assignee: Toray Industries, Inc.Inventors: Satoshi Minakami, Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
-
Publication number: 20210000817Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.Type: ApplicationFiled: March 30, 2018Publication date: January 7, 2021Inventors: Satoshi Minakami, Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
-
Publication number: 20190262270Abstract: A solid preparation includes a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, which is stable to light even without light shielding coating. The solid preparation includes an active ingredient composed of a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, and one or more stabilizing agents selected from the group consisting of n-propyl gallate, sodium hydrogensulfite, dibutylhydroxytoluene, butylhydroxyanisole, tocopherol and D-isoascorbic acid, wherein the amount of the above active ingredient is 0.00001 to 0.01% by weight of the solid preparation, and the amount of the above stabilizing agent is 0.005 to 5% by weight of the solid preparation.Type: ApplicationFiled: July 28, 2017Publication date: August 29, 2019Applicant: Toray Industries, Inc.Inventors: Suguru TAKAKI, Satoshi MINAKAMI, Kotoe OHTA
-
Publication number: 20180338927Abstract: In a system where phase separation into two phases occurs when an ether cellulose derivative (A), a polymer (B) different from the ether cellulose derivative (A), and an alcohol solvent (C) are mixed together, the two phases including a solution phase mainly containing the ether cellulose derivative (A) and a solution phase mainly containing the polymer (B), the two separated phases containing approximately the same solvent, an emulsion is formed and brought into contact with a poor solvent (D) to provide an ether cellulose derivative microparticle having an average particle diameter of 1 to 1,000 ?m, a linseed oil absorption of 50 to 1,000 mL/100 g, and an average surface pore size of 0.05 to 5 ?m.Type: ApplicationFiled: October 26, 2016Publication date: November 29, 2018Inventors: Takahiko Otsubo, Kotoe Ohta, Yuji Echigo, Hiroshi Takezaki, Suguru Takaki, Satoshi Minakami, Akinori Ito, Hisashi Miyama
-
Patent number: 10022331Abstract: A coating agent imparts gas barrier properties to a solid preparation while keeping rapid disintegration properties of the solid preparation, and a coating formed therewith, and provides a coated solid preparation that maintains its rapid disintegration properties and gas barrier properties, and does not generate cracks in the coating under humidified conditions. The coating agent for a solid preparation contains lactose and a swelling clay, but does not contain a water-soluble polymer, wherein the weight of the swelling clay is 20 to 50% with respect to the weight of the solid content.Type: GrantFiled: March 31, 2015Date of Patent: July 17, 2018Assignee: Toray Industries, Inc.Inventors: Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
-
Publication number: 20170105940Abstract: A coating agent imparts gas barrier properties to a solid preparation while keeping rapid disintegration properties of the solid preparation, and a coating formed therewith, and provides a coated solid preparation that maintains its rapid disintegration properties and gas barrier properties, and does not generate cracks in the coating under humidified conditions. The coating agent for a solid preparation contains lactose and a swelling clay, but does not contain a water-soluble polymer, wherein the weight of the swelling clay is 20 to 50% with respect to the weight of the solid content.Type: ApplicationFiled: March 31, 2015Publication date: April 20, 2017Inventors: Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
-
Patent number: 9381248Abstract: A coating agent for a pharmaceutical solid preparation imparts an unpackaged pharmaceutical solid preparation with excellent barrier properties equivalent to those of a PTP sheet without affecting the disintegration properties of the pharmaceutical solid preparation. The coating agent for a pharmaceutical solid preparation includes a polyethylene glycol having an average molecular weight of 950 to 25,000 and a swelling clay, wherein the mass ratio of the polyethylene glycol and the swelling clay is 2:8 to 6:4.Type: GrantFiled: August 31, 2011Date of Patent: July 5, 2016Assignee: Toray Industries, Inc.Inventors: Yuki Fujisaki, Ryoji Yoshii, Suguru Takaki
-
Patent number: 8829019Abstract: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient.Type: GrantFiled: October 23, 2009Date of Patent: September 9, 2014Assignee: Toray Industries, Inc.Inventors: Kotoe Ohta, Suguru Takaki, Yasuhide Horiuchi
-
Patent number: 8715730Abstract: The present invention relates to a stable orally disintegrating coated tablet containing a drug, wherein the tablet is coated with a coating layer containing a water-soluble substance and a polyvinyl alcohol resin of not less than 5% by weight based on the weight of the coating layer, the water-soluble substance dissolving in an amount of 1 g or more in less than 10 mL of water at 20° C., having a hydroxyl group(s) in its molecule, and having a molecular weight of not more than 200 per a unit hydroxyl group. There is provided a stable orally disintegrating coated tablet which does not cause a crack in the coating layer even when the orally disintegrating tablet has been swollen by moisture absorption under high humidity, while ensuring rapid disintegration properties in an oral cavity. In the case of an orally disintegrating tablet containing a light-unstable drug, degradation of the drug can be suppressed by blending a light shading agent in the coating layer.Type: GrantFiled: March 29, 2010Date of Patent: May 6, 2014Assignee: Toray Industries, Inc.Inventors: Suguru Takaki, Kotoe Ohta, Yasuhide Horiuch
-
Publication number: 20130156829Abstract: A coating agent for a pharmaceutical solid preparation imparts an unpackaged pharmaceutical solid preparation with excellent barrier properties equivalent to those of a PTP sheet without affecting the disintegration properties of the pharmaceutical solid preparation. The coating agent for a pharmaceutical solid preparation includes a polyethylene glycol having an average molecular weight of 950 to 25,000 and a swelling clay, wherein the mass ratio of the polyethylene glycol and the swelling clay is 2:8 to 6:4.Type: ApplicationFiled: August 31, 2011Publication date: June 20, 2013Applicant: TORAY INDUSTRIES, INC.Inventors: Yuki Fujisaki, Ryoji Yoshii, Suguru Takaki
-
Patent number: 8420662Abstract: It is an object of the present invention to provide a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the present invention provides the stable solid preparation comprising the 4,5-epoxymorphinan derivative or the pharmacologically acceptable acid addition salt thereof as the effective ingredient, and comprising sodium thiosulfate, a sugar or a sugar alcohol and hydroxypropylcellulose having a low degree of substitution in an amount of 1 to 30% by weight per weight of a unit containing the effective ingredient.Type: GrantFiled: April 25, 2008Date of Patent: April 16, 2013Assignee: Toray Industries, Inc.Inventors: Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi, Masato Kobayashi, Junko Kawasaki, Eijiro Horisawa
-
Publication number: 20120114752Abstract: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient.Type: ApplicationFiled: October 23, 2009Publication date: May 10, 2012Applicant: TORAY INDUSTRIES, INC.Inventors: Kotoe Ohta, Suguru Takaki, Yasuhide Horiuchi
-
Publication number: 20120058186Abstract: The present invention relates to a stable orally disintegrating coated tablet containing a drug, wherein the tablet is coated with a coating layer containing a water-soluble substance and a polyvinyl alcohol resin of not less than 5% by weight based on the weight of the coating layer, the water-soluble substance dissolving in an amount of 1 g or more in less than 10 mL of water at 20° C., having a hydroxyl group(s) in its molecule, and having a molecular weight of not more than 200 per a unit hydroxyl group. There is provided a stable orally disintegrating coated tablet which does not cause a crack in the coating layer even when the orally disintegrating tablet has been swollen by moisture absorption under high humidity, while ensuring rapid disintegration properties in an oral cavity. In the case of an orally disintegrating tablet containing a light-unstable drug, degradation of the drug can be suppressed by blending a light shading agent in the coating layer.Type: ApplicationFiled: March 29, 2010Publication date: March 8, 2012Applicant: TORAY INDUSTRIES, INC.Inventors: Suguru Takaki, Kotoe Ohta, Yasuhide Horiuch
-
Publication number: 20100120815Abstract: It is an object of the present invention to provide a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the present invention provides the stable solid preparation comprising the 4,5-epoxymorphinan derivative or the pharmacologically acceptable acid addition salt thereof as the effective ingredient, and comprising sodium thiosulfate, a sugar or a sugar alcohol and hydroxypropylcellulose having a low degree of substitution in an amount of 1 to 30% by weight per weight of a unit containing the effective ingredient.Type: ApplicationFiled: April 25, 2008Publication date: May 13, 2010Inventors: Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi, Masato Kobayashi, Junko Kawasaki, Eijiro Horisawa